Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection



Status:Completed
Conditions:Anemia, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:2 - 65
Updated:11/24/2017
Start Date:September 2008
End Date:December 2009

Use our guide to learn which trials are right for you!

A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients

The purpose of this study is to determine the pharmacokinetics and safety of Antihemophilic
factor, recombinant, manufactured protein-free (rAHF-PFM) reconstituted in 2 mL sterile water
for injection (SWFI) and compare with those of rAHF-PFM reconstituted in 5 mL of SWFI.


Inclusion Criteria:

- The subject or subject's legally authorized representative has provided written
informed consent

- The subject has severe hemophilia A as defined by a baseline FVIII activity <= 1% of
normal; tested at screening

- The adolescent/adult subject has a documented history of at least 150 exposure days to
FVIII concentrates (either plasma-derived or recombinant), and the pediatric subject
has at least 50 exposure days

- The subject is >= 12 to <= 65 years of age for the complete pharmacokinetic assessment
and >= 2 to < 12 years for the incremental recovery assessment The subject has a
Karnofsky performance score > 60

- The subject is human immunodeficiency virus negative (HIV-) or HIV+ with stable CD4
count >= 200 cells/mm³ (CD4 count determined at screening, if necessary)

Exclusion Criteria:

- The subject has a known hypersensitivity to mouse or hamster proteins or to FVIII
concentrates

- The subject has a history of FVIII inhibitors with titer >= 0. 5 BU (Bethesda Assay)
or >= 0.4 BU (Nijmegen modification of the Bethesda Assay) any time prior to screening

- The subject has a detectable FVIII inhibitor at screening, >= 0.4 BU (Nijmegen
modification of the Bethesda Assay), in the central laboratory

- The subject has severe chronic liver disease as evidenced by, but not limited to, any
of the following: International Normalized Ratio (INR) > 1.4, hypoalbuminemia, portal
vein hypertension including presence of otherwise unexplained splenomegaly and history
of esophageal varices

- The subject has been diagnosed with an inherited or acquired hemostatic defect other
than hemophilia A (e.g. qualitative platelet defect or Von Willebrand Disease)

- The subject has received another investigational product within 30 days of enrollment

- The subject's clinical condition may require major or moderate surgery (estimated
blood loss > 500 mL) during the period of participation in the study

- Subjects with clinically significant medical, psychiatric, or cognitive illness, or
recreational drug/alcohol use that, in the opinion of the investigator, would affect
subject safety or compliance

- The subject is a female of childbearing potential with a positive pregnancy test at
screening
We found this trial at
11
sites
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Lexington, KY
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
New Brunswick, New Jersey 08901
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Washington, D.C.,
Click here to add this to my saved trials